PL1663182T5 - Szybko rozpuszczalna formulacja cynakalcetu HCI - Google Patents

Szybko rozpuszczalna formulacja cynakalcetu HCI

Info

Publication number
PL1663182T5
PL1663182T5 PL04781429T PL04781429T PL1663182T5 PL 1663182 T5 PL1663182 T5 PL 1663182T5 PL 04781429 T PL04781429 T PL 04781429T PL 04781429 T PL04781429 T PL 04781429T PL 1663182 T5 PL1663182 T5 PL 1663182T5
Authority
PL
Poland
Prior art keywords
rapid dissolution
cinacalcet hcl
dissolution formulation
formulation
cinacalcet
Prior art date
Application number
PL04781429T
Other languages
English (en)
Other versions
PL1663182T3 (pl
Inventor
Francisco J. Alvarez
Glen Gary Lawrence
Hung-Ren H. Lin
Tzuchi R. Ju
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1663182(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of PL1663182T3 publication Critical patent/PL1663182T3/pl
Publication of PL1663182T5 publication Critical patent/PL1663182T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04781429T 2003-09-12 2004-09-10 Szybko rozpuszczalna formulacja cynakalcetu HCI PL1663182T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
PCT/US2004/026732 WO2005034928A1 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound
EP04781429.8A EP1663182B2 (en) 2003-09-12 2004-09-10 RAPID DISSOLUTION FORMULATION OF CINACALCET HCl

Publications (2)

Publication Number Publication Date
PL1663182T3 PL1663182T3 (pl) 2013-06-28
PL1663182T5 true PL1663182T5 (pl) 2020-07-27

Family

ID=34434844

Family Applications (6)

Application Number Title Priority Date Filing Date
PL17185704T PL3260117T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl
PL18175495T PL3395338T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl
PL14163366T PL2821067T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczający się preparat cynakalcetu
PL18175499T PL3395340T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl
PL18175497T PL3395339T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl
PL04781429T PL1663182T5 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczalna formulacja cynakalcetu HCI

Family Applications Before (5)

Application Number Title Priority Date Filing Date
PL17185704T PL3260117T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl
PL18175495T PL3395338T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl
PL14163366T PL2821067T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczający się preparat cynakalcetu
PL18175499T PL3395340T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl
PL18175497T PL3395339T3 (pl) 2003-09-12 2004-09-10 Szybko rozpuszczająca się formulacja cynakalcetu HCl

Country Status (30)

Country Link
US (7) US7829595B2 (pl)
EP (8) EP3395339B8 (pl)
JP (3) JP5026077B2 (pl)
KR (1) KR101332058B1 (pl)
CN (1) CN1946382B (pl)
AR (1) AR045637A1 (pl)
AU (1) AU2004279318C1 (pl)
BR (2) BRPI0414254B8 (pl)
CA (1) CA2536487C (pl)
CY (5) CY1119609T1 (pl)
DE (1) DE19164145T1 (pl)
DK (6) DK3260117T3 (pl)
EA (1) EA013425B1 (pl)
ES (7) ES2812198T1 (pl)
HR (1) HRP20130114T4 (pl)
HU (5) HUE044279T2 (pl)
IL (1) IL173737A (pl)
IS (1) IS3027B (pl)
MX (1) MXPA06002616A (pl)
MY (1) MY142046A (pl)
NO (1) NO335739B1 (pl)
NZ (1) NZ545498A (pl)
PL (6) PL3260117T3 (pl)
PT (6) PT3260117T (pl)
SG (1) SG146608A1 (pl)
SI (6) SI2821067T1 (pl)
TR (4) TR201909267T4 (pl)
TW (1) TWI344363B (pl)
WO (1) WO2005034928A1 (pl)
ZA (1) ZA200602710B (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG146608A1 (en) 2003-09-12 2008-10-30 Amgen Inc Dw Us Rapid dissolution formulation of a calcium receptor-active compound
US7495103B2 (en) 2004-06-24 2009-02-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
KR20070116286A (ko) * 2005-05-16 2007-12-07 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 염산염의 제조 방법
MX2007000982A (es) * 2005-05-23 2007-04-16 Teva Pharma Clorhidrato de cinacalcet amorfo y preparacion del mismo.
ES2334260T3 (es) * 2005-05-23 2010-03-08 Teva Pharmaceutical Industries Ltd. Procedimientos para la preparacion de la forma i cristalina de clorhidrato de cinacalcet.
CN102048734B (zh) 2005-05-26 2013-11-20 大日本住友制药株式会社 药物组合物
JP5244597B2 (ja) * 2005-09-02 2013-07-24 アムジエン・インコーポレーテツド カルシリティック化合物またはカルシウム模倣性化合物を用いて腸液バランスを調節する方法
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
JP5309014B2 (ja) * 2006-03-23 2013-10-09 アムジエン・インコーポレーテツド シナカルセットの多形体の製造および使用のための方法および組成物
JP2009535350A (ja) * 2006-04-27 2009-10-01 テバ ファーマシューティカル インダストリーズ リミティド シナカルセット塩基の調製法
EP1915335B1 (en) * 2006-04-27 2009-11-04 Teva Pharmaceutical Industries Ltd Process for the preparation of cinacalcet base
SI2037936T1 (sl) 2006-06-21 2014-11-28 Opko Renal, Llc Postopek zdravljenja in prepreäśevanja sekundarnega hiperparatiroidizma
WO2008000422A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag Amorphous form of cinacalcet
US20080181959A1 (en) * 2006-09-01 2008-07-31 Ilan Zalit Solid composites of a calcium receptor-active compound
US20080146845A1 (en) * 2006-11-20 2008-06-19 Boaz Gome Process for preparing Cinacalcet
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
EP2148684B1 (en) 2007-04-25 2013-01-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
SI2481400T1 (sl) 2007-04-25 2014-11-28 Opko IP Holdings II, Inc. Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec
WO2009002427A2 (en) 2007-06-21 2008-12-31 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
WO2010071689A2 (en) * 2008-05-05 2010-06-24 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl]-1-aminopropane derivative
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010034497A2 (de) 2008-09-25 2010-04-01 Ratiopharm Gmbh Kompaktiertes cinacalcet
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
SMT201700593T1 (it) 2009-03-20 2018-03-08 Vertex Pharma Procedimento per preparare modulatori di regolatore di conduttanza transmembrana di fibrosi cistica
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2435400A2 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
LT2552484T (lt) 2010-03-29 2020-04-27 Opko Ireland Global Holdings, Ltd. Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
WO2012021629A2 (en) 2010-08-11 2012-02-16 Philadelphia Health & Education Corporation Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
CA2818565A1 (en) * 2010-11-23 2012-05-31 Amgen Inc. Pediatric formulation
JP2014507375A (ja) 2010-11-26 2014-03-27 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
JP2014508103A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
CN103228619A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 钙传感受体活性化合物
KR20140108562A (ko) * 2011-12-19 2014-09-11 암젠 인코퍼레이티드 변이체 액티빈 수용체 폴리펩티드 단독 또는 화학 치료법과의 결합, 및 그들의 용도
WO2013107503A1 (en) 2012-01-17 2013-07-25 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
DK2730279T3 (en) * 2012-11-09 2015-10-26 K H S Pharma Holding Gmbh CINACALCETFORMULERINGER immediate release
PL2919903T3 (pl) 2012-11-14 2020-12-14 W.R. Grace & Co. - Conn. Kompozycje zawierające materiał biologicznie aktywny i nieuporządkowany tlenek nieorganiczny
WO2014096277A1 (en) * 2012-12-21 2014-06-26 Synthon B.V. Tablet composition comprising cinacalcet hydrochloride
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CA2915432C (en) * 2013-06-26 2019-03-05 Jubilant Life Sciences Limited Disintegrant free composition of cinacalcet
WO2015136329A1 (en) * 2014-03-14 2015-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
TW201735928A (zh) 2016-03-31 2017-10-16 大日本住友製藥股份有限公司 溶出性優異之口服製劑
WO2019034981A1 (en) * 2017-08-16 2019-02-21 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING CINACALCET CHLORHYDRATE AND ONE OR MORE BINDERS
WO2019186516A1 (en) 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
BR112022017133A2 (pt) * 2020-02-29 2022-10-11 Kempharm Inc Composições compreendendo pró-drogas de metilfenidato, processos de fabricação e uso das mesmas
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
NZ226696A (en) 1987-11-02 1991-10-25 Merck & Co Inc Tablet composition comprising a phthalazine acetic acid derivative as the active ingredient present in from 83-88 wt%
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
EP0373417A1 (en) 1988-11-30 1990-06-20 Schering Corporation Sustained release diltiazem formulation
NZ231897A (en) 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ES2256370T3 (es) 1991-08-23 2006-07-16 Nps Pharmaceuticals, Inc. Moleculas activas para el receptor de calcio.
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
PT724561E (pt) 1991-08-23 2004-07-30 Nps Pharma Inc Arilalquil-aminas como receptores activos de calcio
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
ATE267009T1 (de) 1993-02-23 2004-06-15 Brigham & Womens Hospital Calciumrezeptoraktive moleküle
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
ZA956029B (en) * 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
HU229474B1 (en) 1994-10-21 2014-01-28 Nps Pharma Inc Calcium receptor-active compounds, pharmaceutical compositions containing them and use of the compositions
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
ES2201300T3 (es) 1996-05-01 2004-03-16 Nps Pharmaceuticals, Inc. Compuestos activos frente a receptores de iones inorganicos.
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
JP4331264B2 (ja) 1996-07-08 2009-09-16 協和発酵キリン株式会社 カルシウムレセプター活性化合物
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
JP2002505269A (ja) 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
WO2000021910A2 (en) 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
KR20010104684A (ko) 1998-11-23 2001-11-26 죤 에이치. 뷰센 고농축 수성 글리포세이트 조성물
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
CA2394222A1 (en) 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1272181A2 (en) 2000-04-13 2003-01-08 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
EP1319409A4 (en) 2000-09-22 2006-05-03 Takeda Pharmaceutical SOLID PREPARATIONS
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (pl) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
CA2448864C (en) 2001-06-22 2008-04-22 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
WO2003086343A2 (en) 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20040082588A1 (en) 2002-09-30 2004-04-29 Schering Corporation Methods for treating disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
SG146608A1 (en) 2003-09-12 2008-10-30 Amgen Inc Dw Us Rapid dissolution formulation of a calcium receptor-active compound
EP1930011B1 (en) 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
WO2009111876A1 (en) 2008-03-11 2009-09-17 The University Of Western Ontario System and method for magnetic resonance imaging

Also Published As

Publication number Publication date
IS8324A (is) 2006-02-23
SI3395338T1 (sl) 2019-08-30
US20110136915A1 (en) 2011-06-09
SG146608A1 (en) 2008-10-30
NO20061640L (no) 2006-06-12
PL3395339T3 (pl) 2019-09-30
NZ545498A (en) 2010-04-30
AU2004279318B2 (en) 2010-02-25
CN1946382B (zh) 2010-12-08
SI2821067T1 (en) 2018-03-30
JP2007505108A (ja) 2007-03-08
EP3260117A1 (en) 2017-12-27
HUE044279T2 (hu) 2019-10-28
CA2536487C (en) 2011-10-25
US20190117592A1 (en) 2019-04-25
EP2821067B1 (en) 2017-10-25
DK1663182T3 (da) 2013-04-15
PT1663182E (pt) 2013-03-14
PL1663182T3 (pl) 2013-06-28
JP5849015B2 (ja) 2016-01-27
US20210052518A1 (en) 2021-02-25
JP2012197280A (ja) 2012-10-18
ES2737348T3 (es) 2020-01-13
TR201910180T4 (tr) 2019-07-22
DK3395338T3 (da) 2019-07-22
DK3395340T3 (da) 2019-07-15
BRPI0414254A (pt) 2006-11-07
ZA200602710B (en) 2007-04-25
ES2735226T3 (es) 2019-12-17
PT3395338T (pt) 2019-07-23
JP5026077B2 (ja) 2012-09-12
HUE044822T2 (hu) 2019-11-28
EA200600566A1 (ru) 2006-08-25
US7829595B2 (en) 2010-11-09
DK1663182T4 (da) 2020-02-17
SI3395340T1 (sl) 2019-08-30
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
WO2005034928A1 (en) 2005-04-21
BRPI0414254B8 (pt) 2021-05-25
NO335739B1 (no) 2015-02-02
EP3395340B1 (en) 2019-04-17
PT2821067T (pt) 2017-12-01
CY1121812T1 (el) 2020-07-31
EA013425B1 (ru) 2010-04-30
KR20070017460A (ko) 2007-02-12
DK3395339T3 (da) 2019-07-22
AU2004279318A1 (en) 2005-04-21
EP3260117B1 (en) 2019-04-17
US20200222340A1 (en) 2020-07-16
EP3260117B8 (en) 2019-11-27
DK3260117T3 (da) 2019-07-01
EP3395339B8 (en) 2019-12-11
PL3395338T3 (pl) 2019-10-31
AU2004279318C1 (en) 2020-06-25
ES2812198T1 (es) 2021-03-16
EP2821067A1 (en) 2015-01-07
PL3395340T3 (pl) 2019-10-31
HUE045411T2 (hu) 2019-12-30
PL3260117T3 (pl) 2019-10-31
IL173737A (en) 2012-04-30
EP3578175B1 (en) 2022-11-30
SI3395339T1 (sl) 2019-08-30
SI1663182T2 (sl) 2020-02-28
PT3260117T (pt) 2019-07-04
EP3395340A1 (en) 2018-10-31
JP2015007089A (ja) 2015-01-15
AR045637A1 (es) 2005-11-02
IS3027B (is) 2021-03-15
CY1122259T1 (el) 2020-11-25
EP2316442A1 (en) 2011-05-04
HRP20130114T1 (xx) 2013-03-31
ES2655435T3 (es) 2018-02-20
EP3395338B1 (en) 2019-05-01
ES2735216T3 (es) 2019-12-17
ES2401769T3 (es) 2013-04-24
CY1121814T1 (el) 2020-07-31
JP5940120B2 (ja) 2016-06-29
EP3395340B8 (en) 2019-12-11
US20050147669A1 (en) 2005-07-07
IL173737A0 (en) 2006-07-05
HUE035596T2 (en) 2018-05-28
US20160338975A1 (en) 2016-11-24
US9375405B2 (en) 2016-06-28
TR201910177T4 (tr) 2019-08-21
PL2821067T3 (pl) 2018-02-28
TR201910447T4 (tr) 2019-08-21
TR201909267T4 (tr) 2019-07-22
ES2734057T3 (es) 2019-12-04
SI1663182T1 (sl) 2013-05-31
CY1121820T1 (el) 2020-07-31
ES2401769T5 (es) 2020-07-01
DE19164145T1 (de) 2021-04-29
SI3260117T1 (sl) 2019-08-30
EP1663182B2 (en) 2019-11-20
EP3395339B1 (en) 2019-04-17
TW200518743A (en) 2005-06-16
DK2821067T3 (en) 2017-12-04
US20180243238A1 (en) 2018-08-30
EP3395339A1 (en) 2018-10-31
CY1119609T1 (el) 2018-04-04
CA2536487A1 (en) 2005-04-21
BR122018013029B1 (pt) 2022-04-12
TWI344363B (en) 2011-07-01
BRPI0414254B1 (pt) 2021-03-02
MY142046A (en) 2010-08-30
EP1663182A1 (en) 2006-06-07
CN1946382A (zh) 2007-04-11
PT3395339T (pt) 2019-07-15
EP3395338A1 (en) 2018-10-31
PT3395340T (pt) 2019-07-15
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05

Similar Documents

Publication Publication Date Title
HUE044279T2 (hu) Cinakalcet HCl gyors feloldódású készítménye
EP1684689A4 (en) VENLAFAXINE PREPARATION WITH PROLONGED RELEASE
GB0323908D0 (en) Pharmaceutical foam formulation
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
EG24479A (en) Modified release pharmaceutical formulation
GB0318448D0 (en) Formulation
GB0316206D0 (en) Pharmaceutical formulation
IL165069A0 (en) Immediate release pharmaceutical formulation
IL164077A0 (en) Sustained release formulation of tramadol
GB0312195D0 (en) Formulation
GB0320522D0 (en) Formulation
GB0303876D0 (en) Formulation
GB0318663D0 (en) Rolling formulation
GB0310881D0 (en) Pharmaceutical formulation
IL159780A0 (en) Extended release venlafaxine tablet formulation
GB0316538D0 (en) Formulation
GB0308978D0 (en) Formulation
ZA200510326B (en) Dimeticone-containing sustaned formulation
GB0302435D0 (en) Pharmaceutical formulation